Encorafenib
- Generic Name
- Encorafenib
- Brand Names
- Braftovi
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27ClFN7O4S
- CAS Number
- 1269440-17-6
- Unique Ingredient Identifier
- 8L7891MRB6
- Background
Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most fr...
- Indication
Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. It is also indicated in combination with cetuximab for the treatment of adult patients with metastatic colorecta...
- Associated Conditions
- Metastatic Colorectal Cancer (CRC), Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Unresectable Melanoma
- Associated Therapies
- -
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 124
- Registration Number
- NCT05538130
- Locations
- 🇺🇸
MSK Basking Ridge., Basking Ridge, New Jersey, United States
🇺🇸MSK Monmouth., Middletown, New Jersey, United States
🇺🇸MSK Bergen., Montvale, New Jersey, United States
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 84
- Registration Number
- NCT05308446
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Mercy Cancer Center - Carmichael, Carmichael, California, United States
Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Dr. Ronnie Shapira
- Target Recruit Count
- 12
- Registration Number
- NCT05304546
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05260684
- Locations
- 🇺🇸
Pfizer Investigational Site, New York, New York, United States
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 101
- Registration Number
- NCT05217446
- Locations
- 🇺🇸
Mayo Clinic Building - Phoenix, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
🇫🇷Institut Régional du Cancer Montpellier, Montpellier, France
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 63
- Registration Number
- NCT05195632
- Locations
- 🇨🇳
Beijing Chest Hospital, Capital Medical University, Beijing, China
🇨🇳Sichuan Cancer Hospital, Chengdu, China
🇨🇳Beijing Cancer Hospital, Beijing, China
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Erasca, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05039177
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT05026983
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 103
- Registration Number
- NCT05004350
- Locations
- 🇨🇳
Fujian Medical University - Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 3
- Registration Number
- NCT05003622
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.